BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] slipped around -1.34 points on Thursday, while shares priced at $10.47 at the close of the session, down -11.35%. The company report on February 26, 2021 that BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema.
For investors and media only.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of ORLADEYO™ (berotralstat) for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.
Compared to the average trading volume of 8.43M shares, BCRX reached a trading volume of 7799462 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about BioCryst Pharmaceuticals Inc. [BCRX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCRX shares is $11.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for BioCryst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on September 29, 2020. The new note on the price target was released on June 17, 2020, representing the official price target for BioCryst Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $7, while Barclays analysts kept a Overweight rating on BCRX stock. On November 15, 2019, analysts decreased their price target for BCRX shares from 5 to 4.
The Average True Range (ATR) for BioCryst Pharmaceuticals Inc. is set at 0.97, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 32.37. The Price to Book ratio for the last quarter was 55.11, with the Price to Cash per share for the same quarter was set at 0.87.
How has BCRX stock performed recently?
BioCryst Pharmaceuticals Inc. [BCRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.06. With this latest performance, BCRX shares gained by 14.30% in over the last four-week period, additionally plugging by 153.51% over the last 6 months – not to mention a rise of 313.83% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 53.93, with the RSI for the last a single of trading hit 50.55, and the three-weeks RSI is set at 55.98 for BioCryst Pharmaceuticals Inc. [BCRX]. The present Moving Average for the last 50 days of trading for this stock 9.00, while it was recorded at 11.22 for the last single week of trading, and 5.58 for the last 200 days.
BioCryst Pharmaceuticals Inc. [BCRX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and BioCryst Pharmaceuticals Inc. [BCRX] shares currently have an operating margin of -203.66 and a Gross Margin at +91.60. BioCryst Pharmaceuticals Inc.’s Net Margin is presently recorded at -222.99.
Return on Total Capital for BCRX is now -85.02, given the latest momentum, and Return on Invested Capital for the company is -135.90. Return on Equity for this stock declined to -248.94, with Return on Assets sitting at -67.61. When it comes to the capital structure of this company, BioCryst Pharmaceuticals Inc. [BCRX] has a Total Debt to Total Equity ratio set at 221.30. Additionally, BCRX Total Debt to Total Capital is recorded at 68.88, with Total Debt to Total Assets ending up at 48.30. Long-Term Debt to Equity for the company is recorded at 116.84, with the Long-Term Debt to Total Capital now at 36.37.
Reflecting on the efficiency of the workforce at the company, BioCryst Pharmaceuticals Inc. [BCRX] managed to generate an average of -$777,836 per employee. Receivables Turnover for the company is 3.69 with a Total Asset Turnover recorded at a value of 0.30.BioCryst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.50.
Earnings analysis for BioCryst Pharmaceuticals Inc. [BCRX]
With the latest financial reports released by the company, BioCryst Pharmaceuticals Inc. posted -0.24/share EPS, while the average EPS was predicted by analysts to be reported at -0.24/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioCryst Pharmaceuticals Inc. go to 19.90%.
Insider trade positions for BioCryst Pharmaceuticals Inc. [BCRX]
There are presently around $1,269 million, or 69.90% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: BLACKROCK INC. with ownership of 16,259,745, which is approximately 1.981% of the company’s market cap and around 0.60% of the total institutional ownership; BAKER BROS. ADVISORS LP, holding 12,695,818 shares of the stock with an approximate value of $132.93 million in BCRX stocks shares; and VANGUARD GROUP INC, currently with $121.44 million in BCRX stock with ownership of nearly 1.013% of the company’s market capitalization.
Positions in BioCryst Pharmaceuticals Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 97 institutional holders increased their position in BioCryst Pharmaceuticals Inc. [NASDAQ:BCRX] by around 19,311,871 shares. Additionally, 69 investors decreased positions by around 24,469,652 shares, while 24 investors held positions by with 77,445,783 shares. The mentioned changes placed institutional holdings at 121,227,306 shares, according to the latest SEC report filing. BCRX stock had 38 new institutional investments in for a total of 6,703,632 shares, while 16 institutional investors sold positions of 2,953,720 shares during the same period.